Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving the Partial Pressure of Arterial Oxygen and Fraction of Inspired Oxygen Ratio among COVID-19 Patients

created Acute respiratory can occur in patients with COVID-19 due to viral replication and an uncontrolled immune reaction. Therefore, antiviral and anti-inflammatory treatments are of particular interest to clinicians. We compared the efficacy of methylprednisolone and dexamethasone in reducing inflammation and improving the partial pressure of arterial oxygen and fraction of inspired oxygen (PaO2/FiO2 or P/F) ratio in COVID-19 patients. dexamethasone or methylprednisolone. The data were taken from the medical records of the treated patients. Group 1 patients were given dexamethasone 8 mg twice daily, and Group 2 patients were given methylprednisolone 40 mg twice daily for eight days during their stay in our high dependency unit and our Intensive Care Unit. The remaining treatment was the same for both groups using antibiotics and anticoagulation. We reviewed C-reactive protein (CRP), serum ferritin level, and P/F ratio before and after the administration of both drugs for eight days. We used a paired t-test to assess the effectiveness of both drugs on the P/F ratio of participants. The initial mean CRP level of Group 1 was 110.34 mg/L, which decreased to 19.45 mg/L after administration of dexamethasone; similarly, the CRP of Group 2 was 108.65 mg/L, which decreased to 43.82 mg/L after administering methylprednisolone for eight days. Both dexamethasone and methylprednisolone significantly improved the P/F ratio (p<0.05), and dexamethasone was significantly more effective than methylprednisolone (p<0.05).

Although most infected patients undergo an uneventful recovery, approximately 19% of patients experience severe pneumonia and 14% experience a progressive worsening to critical pneumonia [1].
Patients with severe COVID-19 quickly progressed to acute respiratory failure, pulmonary edema, and acute respiratory distress syndrome (ARDS) [2], which occurred not just because of an uncontrolled viral replication but also because of an uncontrolled immune reaction from the host. With the existence of uncontrolled viral replication, the presence of an increased number of damaged epithelial cells and cell debris activate a massive cytokine release, also known as a cytokine storm, with hyperinflammation and immune inhibition, characterized by decreased memory cluster of differentiation-4 þ T helper cells and an increased cluster of differentiation-8 cytotoxic activity [3].
As a result, antiviral and anti-inflammatory treatments have become an increasing concern for clinicians [4]. A randomized clinical study demonstrated that corticosteroid therapy could reduce inflammatory responses, reduce treatment failure, and reduce the time to clinical stability in community-acquired pneumonia without major adverse effects [5].
Recently, Villar et al. reported that early administration of dexamethasone shortened mechanical ventilation time and overall mortality for patients with moderate-to-severe ARDS [6].
Corticosteroid therapy was associated with improved clinical outcomes in severe COVID-19 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 8, 2020. Wang et al. also found that, for patients with severe COVID-19, corticosteroid therapy reduced hospital length of stay and intensive care unit (ICU) stays [8]. Chinese experts considered it prudent to administer short courses of corticosteroids at low-to-moderate doses for critically ill patients with COVID-19 [9]. Wu et al. reported that treatment with methylprednisolone decreased the risk of death for individuals with COVID-19 with ARDS [10].

Objective
Using steroids in moderate to severe disease is a standard practice in management of COVID19 and we have been following the same. Some cases were treated with methylprednisolone where others were treated with equivalent doses of dexamethasone. This has automatically created a patient pool consisting of two groups.
The objective of this study was to assess the effectiveness of dexamethasone and methylprednisolone in COVID-19 patients as well as compare both drugs in regards to partial pressure arterial oxygen and fraction of inspired oxygen (PaO 2 /FiO 2 [P/F]) ratio improvement. A significant amount of research has been published on the effectiveness of steroids in COVID-19 patients, but there is limited literature on comparing the effectiveness of dexamethasone and methylprednisolone.

Hypothesis
We created two hypotheses: the H1 (alternate hypothesis) and the H0 (null hypothesis). The H1 hypothesis states that methylprednisolone and dexamethasone can improve the P/F ratio in . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 8, 2020. ; https://doi.org/10.1101/2020.10.06.20171579 doi: medRxiv preprint COVID-19 patients. The H0 hypothesis states that methylprednisolone and dexamethasone cannot improve the P/F ratio in COVID-19 patients.

Materials and Methods
We used a retrospective quasi-experimental study design to assess the effectiveness of methylprednisolone and dexamethasone in the improvement of the P/F ratio in COVID-19 patients. We used a convenient sampling technique to select files (medical record) of 60 participants, all of whom had been admitted and treated in the HDU/ICU and had been on bilevel positive airway pressure. These 60 patients (medical records) were divided into two groups: Group 1 who had received dexamethasone, and Group 2 who had received methylprednisolone.
Each group consisted of 30 participants (medical records of 30 patients). It needs to be reemphasized that these cases were already treated and had been concluded. They were treated by different treating teams. One group was pro-dexamethasone who used to give dexamethasone to their patients while other team had been favoring and used methylprednisolone in equivalent doses to dexamethasone. Apart from the type of steroid used all other management was same for both groups of patients including anticoagulation and we would like to declare that both groups were on therapeutic anticoagulants. We had administered dexamethasone 8 mg twice daily to one Group (labelled as Group 1) participants and methylprednisolone 40 mg twice daily (almost equivalent dose to dexamethasone) to now labelled as Group 2 participants. The duration of treatment compared was for eight days. Laboratory specimens were being sent daily during the morning shifts to enable the treating clinicians to take decisions during their treatment periods.
We have chosen two sets laboratory values for this study one set which was taken on the first day of hospitalization and second set from eighth day of administration of drugs, from their medical records. Similarly for the P/F ratio comparison, we took the PaO 2 values from their daily . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 8, 2020. ; https://doi.org/10.1101/2020.10.06.20171579 doi: medRxiv preprint morning arterial blood gas reports, two sets again. For data analysis, we described demographic data in descriptive form (frequencies and percentages); laboratory values were analyzed in the form of mean, and comparison between dexamethasone and methylprednisolone effectiveness of the P/F ratio was analyzed using a paired t-test.

Results
Our results are presented in three parts. Part I includes demographic characteristics of participants, Part II includes outcomes of laboratory value changes in response to dexamethasone and methylprednisolone, and Part III includes a comparison of outcomes in response to both drugs.
Part I Sixty patients' medical records was selected for this study, with 30 participants in each group.
Group 1 which had received dexamethasone for eight days, and Group 2 which had received methylprednisolone for eight days. Both groups were on therapeutic anticoagulants. In Group 1, 33.33% were women, and 66.67% were men; similarly, in the Group 2, 30% were women, and 70% were men (Figure 1). The mean age of Group 1 was 53.8 years, and the mean age of Group 2 was 53.9 years (Table 1).
. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 8, 2020. ;  Part II

Figure Legend
In this section, we discussed the changes that occurred in laboratory values of patients before and after administration of dexamethasone and methylprednisolone and how effectively dexamethasone and methylprednisolone worked. In Table 2, the CRP difference is shown. The initial mean CRP of Group 1 was 110.34 mg/L, which decreased to 19.45 mg/L after administration of dexamethasone and was considered a good reduction in CRP value. Mean nd . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 8, 2020. ; https://doi.org/10.1101/2020.10.06.20171579 doi: medRxiv preprint inflammation was reduced in the maximum range; similarly, the CRP of Group 2 was 108.65 mg/L, which decreased to 43.82 after the administration of methylprednisolone for eight days. In Table 3, serum ferritin levels are shown. The initial mean serum ferritin of Group 1 was 763 ng/mL, which decreased to 494.30 ng/mL after administration of dexamethasone for eight days. Similarly, the serum ferritin level of Group 2 was 631.53 ng/mL, which decreased to 493.07 ng/mL after administration of methylprednisolone for eight days.  . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 8, 2020. ; Part III This section consisted of outcomes comparison after administering methylprednisolone and dexamethasone. As mentioned previously, the main focus of this study was to assess the effectiveness of dexamethasone and methylprednisolone on the P/F ratio. To compare the preand post-P/F ratio, we applied a paired sample t-test to check the effectiveness of both drugs.
Findings revealed that the mean P/F ratio after dexamethasone (170.4130) was significantly higher than the mean P/F ratio before dexamethasone (118.2067; p=.000). Similarly, the P/F ratio after methylprednisolone (136.2575) was higher than the P/F ratio before administration methylprednisolone (105.6609) for eight days (p=.009; Table 5). As these p-values indicate, dexamethasone improved the P/F ratio significantly more than methylprednisolone.
The H1 alternate hypothesis (methylprednisolone and dexamethasone are effective in improving P/F ratio in COVID-19 patients) can be accepted, and the H0 null hypothesis (methylprednisolone and dexamethasone could not improve the P/F ratio in COVID-19 patients) can be rejected on the basis of the paired t-test.
. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted October 8, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted October 8, 2020. ; https://doi.org/10.1101/2020.10.06.20171579 doi: medRxiv preprint There were certain limitations of the present study. We did not include a control group, did not assess any underlying comorbidities, and did not compare the effectiveness of steroid therapy in regard to age, sex, and severity of illness. Randomized controlled clinical trials are required to confirm the effectiveness and safety of corticosteroid therapy and to further study the long-term outcomes after discharge with a large sample size for better generalization of findings.

Conclusion
Steroids have long been known to reduce inflammation and suppress immune reactions. These actions make steroids an effective tool in the treatment of COVID-19, and they have become a standard of treatment all over the world. Dexamethasone is more effective in improving the P/F ratio in COVID-19 patients compared to methylprednisolone. Physicians should consider the use of dexamethasone use in appropriate patients with COVID-19.